Literature DB >> 16563084

Erlotinib or capecitabine with gemcitabine in pancreatic cancer?

Jenny de Jager, Justin Stebbing.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16563084     DOI: 10.2217/14796694.2.2.161

Source DB:  PubMed          Journal:  Future Oncol        ISSN: 1479-6694            Impact factor:   3.404


× No keyword cloud information.
  1 in total

1.  MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.

Authors:  Wenqing Qi; Larry S Cooke; Amy Stejskal; Christopher Riley; Kimiko Della Croce; Jose W Saldanha; David Bearss; Daruka Mahadevan
Journal:  BMC Cancer       Date:  2009-05-11       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.